SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Aug 22, 16:20
648.75
-4.8 (-0.73%)
VOLUME 142,918
LIVE
NSE
Aug 22, 16:20
648.60
-4.45 (-0.68%)
VOLUME 789,047
Earnings News on Ranbaxy Laboratories
Select Year: 2013 |  2012 |  2011 | 2010 | 2009 | 2008 | 2007 | 2000-2006
AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

3.31 pm | 31 Jul 2014 |  Source: Reuters

On the back of the strong results, AstraZeneca raised its guidance for the full year, predicting sales would hold steady and not decline as previously...

Dr Reddy's, Lupin, Glenmark top pharma bets: Nomura 

11.25 am | 31 Jul 2014 |  Source: CNBC-TV18

"We have a buy recommendation on both Sun Pharma and Ranbaxy at this point," Saion Mukherjee, research analyst Nomura said....

Ranbaxy Q1 disappoints, posts loss at Rs 186cr on provision 

5.14 pm | 29 Jul 2014 |  Source: CNBC-TV18

Consolidated revenue of the company fell 9.6 percent on yearly basis to Rs 2,426.2 crore due to lower exports (declined over 13 percent) while domesti...

Ranbaxy Labs may post Q1 profit Rs 27 cr vs loss YoY: Poll 

6.15 pm | 28 Jul 2014 |  Source: CNBC-TV18

Analysts feel operating profit (EBITDA) may be impacted due to consent decree costs that is expected to be in single digits. They expect mark-to-marke...

Ranbaxy disappoints; lower EBITDA at 6% main cause: Angel 

6.17 pm | 09 May 2014 |  Source: CNBC-TV18

EBITDA margins is something which will take sometime to be steady for Ranbaxy. It will hover around 6-8 percent range unless other core issues get res...

Ranbaxy March quarter net loss at Rs 73.6cr

3.47 pm | 09 May 2014 |  Source: PTI

During the quarter, the company recorded inventory and other costs write-off and goodwill impairment write-off of Rs 15.9 crore and Rs 43.8 crore resp...

Ranbaxy Q5 net may rise 20.5% at Rs 102.1 cr: Motilal Oswal

8.39 am | 09 May 2014 |  Source: Moneycontrol.com

Sales are expected to decrease by 5.6 percent Q-o-Q (up 11.6 percent Y-o-Y) to Rs 2730.8 crore, according to Motilal Oswal....

Pharma cos may see healthy earnings growth in Q4FY14: CLSA

12.36 pm | 03 Apr 2014 |  Source: Moneycontrol.com

Most companies are expected to report some forex gains on hedges and foreign liabilities given the slight strengthening of rupee Q-o-Q, CLSA said....

1
Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.